Publication: Somatostatin receptor tumor imaging (Tc 99m P829) in pituitary adenoma
Issued Date
1999-12-01
Resource Type
ISSN
01252208
Other identifier(s)
2-s2.0-0033491473
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of the Medical Association of Thailand. Vol.82, No.12 (1999), 1208-1213
Suggested Citation
S. Chiewvit, P. Pusuwan, V. Ratanamart, P. Chiewvit, S. Sriussadaporn Somatostatin receptor tumor imaging (Tc 99m P829) in pituitary adenoma. Journal of the Medical Association of Thailand. Vol.82, No.12 (1999), 1208-1213. Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/25503
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Somatostatin receptor tumor imaging (Tc 99m P829) in pituitary adenoma
Other Contributor(s)
Abstract
Technetium 99m P829 (99mTc P829) is a somatostatin like structure labelled with Technetium-99m. Somatostatin receptor positive tumors such as pituitary tumors, neuroendocrine tumors, and lymphomas show positive scintigraphy. Eleven patients suspected of having a pituitary mass (12 studies) were studied with 99mTc P829. Three pituitary adenoma patients (4 studies) showed positive somatostatin receptor tumor imaging. Eight negative somatostatin receptor scintigraphy were one hypothyroid induced pituitary hyperplasia, one craniopharyngioma, one normal pituitary tissue with focal hyperplasia, one ACTH secreting pituitary tumor, one GH, PRL secreting pituitary tumor post transphenoidal partial tumor removal, and no surgery in 3 patients. Finally, somatostatin receptor imaging may be useful as a tumor localizing technique in addition to conventional CT and MRI imaging and identify patients who might potentially benefit from octreotide treatment. In addition, the development of peptide analogs coupling to β-emitting radiopharmaceutical may lead to a situation in which diagnosis peptide receptor scintigraphy can be followed by radionuclide therapy.